Controversies in Nutrient-Specific Therapies: Effective or Ineffective? - PowerPoint PPT Presentation

heba
controversies in nutrient specific therapies effective or ineffective n.
Skip this Video
Loading SlideShow in 5 Seconds..
Controversies in Nutrient-Specific Therapies: Effective or Ineffective? PowerPoint Presentation
Download Presentation
Controversies in Nutrient-Specific Therapies: Effective or Ineffective?

play fullscreen
1 / 38
Download Presentation
105 Views
Download Presentation

Controversies in Nutrient-Specific Therapies: Effective or Ineffective?

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Controversies in Nutrient-Specific Therapies: Effective or Ineffective? Daren K. Heyland MD Professor of MedicineQueen’s University, Kingston, ON Canada On behalf of the REDOXS Study Investigators

  2. Disclosures • Research grants and speaking honorarium from Fresenius Kabi, biosyn, Baxter, Abbott and Nestle • None of these companies have a decisional role in the conception, design, conduct, analysis, interpretation of results or decision to publish.

  3. A RANDOMIZED TRIAL OF HIGH-DOSE GLUTAMINE AND ANTIOXIDANTS IN CRITICALLY ILL PATIENTS WITH MULTIORGAN FAILUREThe REDOXS study Daren K. Heyland MD Professor of MedicineQueen’s University, Kingston, ON Canada On behalf of the REDOXS Study Investigators N Engl J Med 2013;368:1489-97.

  4. The REDOXS study antioxidants Factorial 2x2 design Double blind treatment glutamine R 1200 ICU patients R Concealed Stratified by site placebo Evidence of Multi-organ failure antioxidants R placebo placebo

  5. Mortality Outcomes P=0.02 P=0.02 P=0.049 P=0.07 Note: all P values pertain to GLN vs No GLN; no significant differences between AOX vs. No AOX


  6. Post-hoc Secondary Analyses

  7. Selected Subgroup Analyses No Positive Subgroups

  8. Adjusted Analysis Imbalance in organ failures at baseline?

  9. Adjusted Analysis • The 28-day mortality rates in the placebo, glutamine, antioxidant and combination groups were 25%, 32%, 29% and 33% respectively. • Compared to placebo, the unadjusted OR (95% CI) of mortality was 1.4 (1.0-2.0, P =0.063), 1.2 (0.8-1.7, P =0.31) and 1.4 (1.0-2.0, P=0.049) in the glutamine, antioxidant and combined groups respectively. • After adjusting for all statistically significant baseline characteristics, the corresponding adjusted ORs remained virtually unchanged at: Glutamine 1.4 (1.0-2.1, P =0.054) Antioxidant 1.2(0.8-1.8, P =0.34) Both 1.4 (0.9-2.0, P =0.10)

  10. Conclusions • Glutamine and antioxidants at doses studied in this study do not improve clinical outcomes in critically ill patients with multi-organ failure • Glutamine may be harmful • For both glutamine and antioxidants, the greatest signal of harm was in patients with multi-organ failure that included renal dysfunction upon study enrollment. • Patients with multi-organ failure not uniformly associated with low plasma glutamine levels • May have provided insufficient selenium

  11. e Experimental Diet enriched with Glutamine, AOX, and Omega 3 FFAs EN glutamine associated with increased mortality? A van Zanten, unpublished data

  12. GLN enriched GLN enriched

  13. Where does that leave Glutamine?

  14. Updated Meta-analysis of IV Glutamine (n=24RCTs) Overall Mortality Note: Does not include EN GLN studies nor REDOXS study RR=0.88 (0.75,1.03) p=0.10 Wischmeyer et al (under review)

  15. Updated Meta-analysis of IV Glutamine (n=13RCTs) Hospital Mortality RR=0.68 (0.51,0.90) P= 0.008 Note: Does not include EN GLN studies nor REDOXS study Wischmeyer et al (under review)

  16. Updated Meta-analysis of IV Glutamine (n=13RCTs) Influence of the number of study sites involved in the trial Hospital Mortality Wischmeyer et al (under review)

  17. Updated Meta-analysis of IV Glutamine (n=12 RCTs) Infection Note: Does not include EN GLN studies nor REDOXS study RR=0.86 (0.73,1.02) P=0.10 Wischmeyer et al (under review)

  18. Updated Meta-analysis of IV Glutamine (n=11 RCTs) ICU Length of Stay Note: Does not include EN GLN studies nor REDOXS study WMD=-1.91 (-4.10, -0.28) p=0.09 Wischmeyer et al (under review)

  19. Updated Meta-analysis of IV Glutamine (n= 11 RCTs) Hospital Length of Stay Note: Does not include EN GLN studies nor REDOXS study WMD=-2.56 (-4.71, -0.42) P=0.02 Wischmeyer et al (under review)

  20. Canadian Nutrition CPGs: IV Glutamine Recommendation: • When parenteral nutrition is prescribed to critically ill patients, parenteral supplementation with glutamine should be considered*. • However, we strongly recommend that glutamine NOT be used in critically ill patients with multi-organ failure. • there are insufficient data to generate recommendations for intravenous glutamine in critically ill patients receiving enteral nutrition. *downgraded from ‘strongly recommend’

  21. Canadian Nutrition CPGs: EN Glutamine • No new studies since 2009 • Conclusions are: • 1) Glutamine supplemented enteral nutrition may be associated with a reduction in mortality in burn patients, but inconclusive in other critically ill patients. • 2) Glutamine supplemented enteral nutrition may be associated with a reduction in infectious complications in burn and trauma patients. • 3) Glutamine supplemented enteral nutrition is associated with a significant reduction in hospital length of stay in burn and trauma patients. • Recommendation: Enteral glutamine should be considered in burn and trauma patients. There are insufficient data to support the routine use of enteral glutamine in other critically ill patients.* *warning against use in multi-organ failure and shock

  22. Canadian Nutrition CPGs: Combined IV+ EN Glutamine Recommendation: • Based on one level 1 study (REDOXS), we strongly recommend that high dose combined parenteral and enteral glutamine supplementation NOT be used in critically ill patients with multi-organ failure.

  23. What does the updated meta-analyses say on antioxidant supplementation in the critically ill?

  24. Combined Antioxidants: effect on mortality (n =23) 0.86 (0.75-0.99) p= 0.03 www.criticalcarenutrition.com

  25. Selenium supplementation and ICU infectious complications, (n =8) 0.88(0.78-0.99) www.criticalcarenutrition.com

  26. Update Canadian CPGs: Combined Antioxidants • still significant reduction in mortality & infections • despite results of large RCT (REDOXS) that showed no effect (could be related to dose?) • heterogeneity of the trials but high generalizability • no concerns about the safety, feasibility and cost of these nutrients 2013 Recommendation: no changes: “should be considered”

  27. Arginine 2009 Recommendation Based on 22 studies, we recommend arginine and other select nutrients not be used for critically ill patients New RCTs = 2 2013: No changes in recommendation 1

  28. Enteral Fish Oils* *Product enhanced with fish oils +borage oils + antioxidants 1

  29. Enteral Fish Oils* *Product enhanced with fish oils +borage oils + antioxidants 2009 Recommendation Based on 5 studies, we recommend the use of enteral formula with fish oils, borage oils, and antioxidants in patients with ALI/ARDS New RCTs = 4 Rice 2011 Grau-Carmona 2011 Thiella 2011 Elamin 2012 + Pontes Arruda 2011 + Stapleton 2011 (fish oil only)

  30. ARDSnet NIH NHLBI Timing of Feeding “Early Trophic” (10 ml/hr) “Early Full” Fast ramp up S U P P L E M E N T N-3 + GLA + Antioxidants (Module delivered as bolus bid) Control Standard EN (480 cal/ 20 g pro)

  31. OMEGA: 60-Day Mortality P=0.14 P=0.14 P=0.05 bolus: dilute effect? 50% pts underfed (trophic) protein in placebo include but analyze without Rice et al JAMA Oct 2011

  32. 11 Spanish ICUs • 89 patients with diagnosis of Sepsis on admission • Randomized to: • Fish Oil/Borage Oil formula OR • Standard polymeric formula • Outcomes: new organ dysfunction Grau-Carmona Clin Nutr 2011

  33. Clinical Outcomes First multicentre study to use “usual care” in control group…….no effect on mortality Grau-Carmona Clin Nutr 2011

  34. Fish Oils: Effect on mortality (n = 6) INTERSEPT, Stapleton data not included No effect , statistical heterogeneity! 2009: RR 0.67, 95% CI 0.51, 0.97, p = 0.003 Dhaliwal R et al NCP 2013 in press

  35. Fish oils: effect on mortality removing bolus RCT (n =5) Significant effect, no statistical heterogeneity! www.criticalcarenutrition.com

  36. EN Fish oils with new RCTs • Effect on mortality disappears when bolus study is included • statistical heterogeneity present • Effect on mortality is significant when bolus study excluded • Infections (2 RCTs): no effect • Reduction in ICU LOS still significant (heterogeneity) • Concerns of control group, negative results of large studies 2013 Recommendations Fish Oils/borage oil: Downgraded recommendation to “should be considered” Fish Oils alone: insufficient data

  37. Questions?